- Home
- EKSO vs NCNA Comparison
EKSO vs NCNA Comparison
Compare EKSO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- NCNA
- Stock Information
- Founded
- EKSO 2005
- NCNA 1997
- Country
- EKSO United States
- NCNA United Kingdom
- Employees
- EKSO N/A
- NCNA N/A
- Industry
- EKSO Medical/Dental Instruments
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- NCNA Health Care
- Exchange
- EKSO Nasdaq
- NCNA Nasdaq
- Market Cap
- EKSO 7.7M
- NCNA 6.6M
- IPO Year
- EKSO N/A
- NCNA 2017
- Fundamental
- Price
- EKSO $3.90
- NCNA $3.96
- Analyst Decision
- EKSO Strong Buy
- NCNA
- Analyst Count
- EKSO 2
- NCNA 0
- Target Price
- EKSO $34.75
- NCNA N/A
- AVG Volume (30 Days)
- EKSO 37.0K
- NCNA 451.8K
- Earning Date
- EKSO 10-27-2025
- NCNA 08-20-2025
- Dividend Yield
- EKSO N/A
- NCNA N/A
- EPS Growth
- EKSO N/A
- NCNA N/A
- EPS
- EKSO N/A
- NCNA N/A
- Revenue
- EKSO $14,651,000.00
- NCNA N/A
- Revenue This Year
- EKSO N/A
- NCNA N/A
- Revenue Next Year
- EKSO $49.96
- NCNA N/A
- P/E Ratio
- EKSO N/A
- NCNA N/A
- Revenue Growth
- EKSO N/A
- NCNA N/A
- 52 Week Low
- EKSO $2.73
- NCNA $2.78
- 52 Week High
- EKSO $19.05
- NCNA $1,182.00
- Technical
- Relative Strength Index (RSI)
- EKSO 53.19
- NCNA 43.35
- Support Level
- EKSO $3.81
- NCNA $2.82
- Resistance Level
- EKSO $4.02
- NCNA $4.88
- Average True Range (ATR)
- EKSO 0.27
- NCNA 0.31
- MACD
- EKSO -0.01
- NCNA 0.46
- Stochastic Oscillator
- EKSO 53.75
- NCNA 55.95
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.